Answers are grounded in this paper and cite their sources.
The Excellence in Oncology Care (EIOC) 2023 Congress, held in Dubai as a hybrid event, brought together oncologists from the Middle East and the Indian subcontinent. Two panels, comprising 33 experts, developed the first region-specific consensus guidelines to address critical issues in non-small cell lung cancer (NSCLC), particularly focusing on the roles of liquid biopsy and targeted therapies in early-stage cancer. These guidelines, created through surveys and preparatory meetings, were presented and discussed at the congress, both in person and online. While tissue biopsies remain the gold standard, liquid biopsies are emerging as a promising, minimally invasive alternative, though they are hampered by a lack of standardization and logistical challenges in the region. Liquid biopsy supports follow-up by accessing circulating tumor DNA, though its utilization is limited by infrastructure and costs. In the Middle East and the Indian subcontinent, the adoption of liquid biopsy is constrained by logistical hurdles, financial limitations, and inadequate infrastructure. The EIOC panels provided consensus statements on employing liquid biopsy and integrating targeted therapy in early-stage and locally advanced NSCLC for this region. The consensus highlighted the importance of combining liquid and tissue biopsies, especially for detecting resistance mutations and driver alterations, such as EGFR and ALK, with recommendations for incorporating targeted therapy and chemotherapy. This consensus aims to assist regional clinicians in navigating the evolving landscape of NSCLC management.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: